BRPI0415232A - uso de xenÈnio com hipotermia para tratar asfixia neonatal - Google Patents

uso de xenÈnio com hipotermia para tratar asfixia neonatal

Info

Publication number
BRPI0415232A
BRPI0415232A BRPI0415232-8A BRPI0415232A BRPI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A
Authority
BR
Brazil
Prior art keywords
xenon
hypothermic
neonatal asphyxia
treat neonatal
asphyxia
Prior art date
Application number
BRPI0415232-8A
Other languages
English (en)
Inventor
Nicholas Peter Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34436835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323861A external-priority patent/GB0323861D0/en
Priority claimed from GB0418539A external-priority patent/GB0418539D0/en
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of BRPI0415232A publication Critical patent/BRPI0415232A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE XENÈNIO COM HIPOTERMIA PARA TRATAR ASFIXIA NEONATAL". A presente invenção refere-se ao uso de xenónio na preparação de um medicamento para o tratamento de asfixia neonatal em um indivíduo neonatal, em que o referido medicamento é para uso em combinação com hipotermia.
BRPI0415232-8A 2003-10-10 2004-10-11 uso de xenÈnio com hipotermia para tratar asfixia neonatal BRPI0415232A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0323861A GB0323861D0 (en) 2003-10-10 2003-10-10 Use
GB0418539A GB0418539D0 (en) 2004-08-19 2004-08-19 Use
PCT/GB2004/004298 WO2005034966A1 (en) 2003-10-10 2004-10-11 Use of xenon with hypothermia for treating neonatal asphyxia

Publications (1)

Publication Number Publication Date
BRPI0415232A true BRPI0415232A (pt) 2006-12-12

Family

ID=34436835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415232-8A BRPI0415232A (pt) 2003-10-10 2004-10-11 uso de xenÈnio com hipotermia para tratar asfixia neonatal

Country Status (13)

Country Link
US (1) US7390508B2 (pt)
EP (1) EP1670489B1 (pt)
JP (1) JP4880466B2 (pt)
AT (1) ATE380554T1 (pt)
AU (1) AU2004280118B2 (pt)
BR (1) BRPI0415232A (pt)
CA (1) CA2538104C (pt)
DE (1) DE602004010691T2 (pt)
DK (1) DK1670489T3 (pt)
ES (1) ES2298815T3 (pt)
MX (1) MXPA06003471A (pt)
PT (1) PT1670489E (pt)
WO (1) WO2005034966A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004280118B2 (en) * 2003-10-10 2009-01-15 Imperial Innovations Limited Use of xenon with hypothermia for treating neonatal asphyxia
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
CA2712516C (en) * 2008-01-22 2016-06-28 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
AU2014233018A1 (en) 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
AU2001247841A1 (en) * 2000-03-31 2001-10-30 Innercool Therapies, Inc. Medical procedure
AU2004280118B2 (en) * 2003-10-10 2009-01-15 Imperial Innovations Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
DE602004010691T2 (de) 2008-12-04
WO2005034966A1 (en) 2005-04-21
CA2538104C (en) 2013-12-10
JP2007508284A (ja) 2007-04-05
US20070104796A1 (en) 2007-05-10
ES2298815T3 (es) 2008-05-16
ATE380554T1 (de) 2007-12-15
CA2538104A1 (en) 2005-04-21
DK1670489T3 (da) 2008-01-07
JP4880466B2 (ja) 2012-02-22
EP1670489A1 (en) 2006-06-21
DE602004010691D1 (de) 2008-01-24
MXPA06003471A (es) 2006-06-14
AU2004280118B2 (en) 2009-01-15
EP1670489B1 (en) 2007-12-12
AU2004280118A1 (en) 2005-04-21
US7390508B2 (en) 2008-06-24
PT1670489E (pt) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
HK1125040A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
BRPI0415232A (pt) uso de xenÈnio com hipotermia para tratar asfixia neonatal
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
PT1220676E (pt) Prevencao do cancro colorrectal
DE602005023742D1 (de) Formulierung von 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-on mit verzögerter freisetzung
EA200801890A1 (ru) Средство для лечения шума в ушах
BRPI0410998A (pt) derivados de indol com efeito de indução de apoptose
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
EA200801023A1 (ru) Применение фенофибрата или его производного для предотвращения диабетической ретинопатии
PL1818052T3 (pl) Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
AR051035A1 (es) Uso de epotilonas en el tratamiento de metastasis en hueso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: PROTEXEON LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: IMPERIAL INNOVATIONS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL